Allergan plc Accounts Payable

The latest accounts payable for AGN is $400M as of March 2020. That compares with $360M in the prior-year period — up 12.7% year over year. Investors often review this figure alongside Allergan plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGN's accounts payable moved from $360M to $400M — a 12.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Allergan plc's operating scale or balance-sheet position.

A accounts payable figure of $400M for AGN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AGN's accounts payable ($400M), review year-over-year change from $360M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Allergan plc's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.